肺癌PD-1/PD-L1抑制剂治疗的耐药机制  

Resistance mechanism of immune checkpoint PD-1/PD-L1 inhibitor therapy for lung cancer

作　　者：薛超[1] 杨凡 管莎莎[1] 千年松[3] 李方[1] Xue Chao;Yang Fan;Guan Shasha;Qian Niansong;Li Fang(Department of Oncology,Hainan Hospital of PLA General Hospital,Hainan,Sanya 572013,China;Department of Oncology,the Fifth Medical Center of PLA General Hospital,Beijing 100039,China;Department of Oncology,the Eighth Medical Center of PLA General Hospital,Beijing 100091,China)

机构地区：[1]解放军总医院海南医院肿瘤内科,海南三亚572013 [2]解放军总医院第五医学中心肿瘤学部肿瘤内科,北京100039 [3]解放军总医院第八医学中心呼吸学部肿瘤内科,北京100091

出　　处：《肿瘤综合治疗电子杂志》2022年第4期105-113,共9页Journal of Multidisciplinary Cancer Management(Electronic Version)

摘　　要：近年来,针对肺癌的治疗药物不断更新进步,其中程序性死亡蛋白-1(programmed death protein-1,PD-1)和程序性死亡蛋白配体-1(programmed death ligand-1,PD-L1)抑制剂通过降低对免疫细胞的抑制、增强机体自身免疫系统的能力,有效提升了抗肿瘤治疗效果,获得了令人瞩目的成就。但随着临床的广泛应用,部分患者表现出的免疫耐药阻碍了其发挥更好的疗效。明确免疫耐药的机制、探索新的治疗靶点和治疗对策也是如今的热点问题。本文主要讨论了PD-1/PD-L1抑制剂的基本作用以及免疫耐药的肿瘤内外机制,旨在推动其为患者带来更多的获益。In recent years,the drugs for lung cancer have been constantly updated and improved,among which programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor have effectively improved the anti-tumor therapeutic effect by reducing the inhibition of immune cells and enhancing the ability of the body’s own immune system,and achieved remarkable achievements.However,with its wide clinical application,some patients show immune resistance,which limits its better efficacy.Researching the mechanism of immune resistance and exploring new therapeutic targets and strategies are hot issues nowadays.This review mainly discusses the basic role of PD-1/PD-L1 inhibitor and the internal and external mechanisms of immune resistance,aiming to promote the benefits of PD-1/PD-L1 inhibitor for more patients.

关 键 词：肺癌 免疫检查点抑制剂 程序性死亡蛋白-1/程序性死亡蛋白配体-1 耐药机制 

分 类 号：R734.2[医药卫生—肿瘤]